Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L), Administered Intratumorally in Subjects With Cutaneous Squamous Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck

NCT04502888 is registered in ClinicalTrials.gov with Shattuck Labs, Inc. as lead sponsor.

NCT NCT04502888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04502888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L), Administered Intratumorally in Subjects With Cutaneous Squamous Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Shattuck Labs, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 17, 2020
Completion date
April 8, 2022
Enrollment
5 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck